Shield Therapeutics Announces Acceptance of ST10 Abstract for Presentation at ECCO Congress 2014
LONDON, February 4, 2014 /PRNewswire/ –
Shield Therapeutics (Shield), an independent specialty pharmaceutical company, today
announces the acceptance of the first peer-reviewed abstract relating to data from the
AEGIS Phase III programme of ST10 for the treatment of iron deficiency anaemia (IDA) in
inflammatory bowel disease (IBD). The data will be presented at the 9th Congress of ECCO,
taking place from February 20 – 22 in Copenhagen, Denmark.
As recently announced, ST10, a novel orally-dosed form of ferric iron, successfully
met both the primary and secondary endpoints of the AEGIS pivotal Phase III programme.
With a mean increase of 2.3g/dL in ST10-treated subjects, the results of the study
strongly demonstrated ST10′s potential to be the only effective oral treatment for ferrous
intolerant IDA patients, in addition to being an effective alternative to intravenous iron
The abstract about ST10, entitled “Correcting iron deficiency anaemia in IBD: A
pivotal phase 3 study of a novel oral ferric iron”, will be presented during the Digital
Oral Poster Session 9 – Therapy today – in Room 9, Hall B on the Ground level of the Bella
Centre at 13.07 on Friday 21st February 2014.
About Shield Therapeutics
Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an
independent specialty pharmaceutical company focused on the development and
commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address
areas of high unmet medical need. Shield has successfully completed a pivotal Phase 3
programme of its lead asset, ST10, for the treatment of iron deficiency anaemia associated
with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the
treatment of iron deficiency anaemia in patients with chronic kidney disease.
For more information about Shield Therapeutics, please contact:
Consilium Strategic Communications Mary-Jane Elliott / Emma Thompson / Lindsey Neville Tel +44(0)20-7920-2333 Email: email@example.com
SOURCE Shield Therapeutics